深圳信立泰药业董事会重大决议详细解读

一、使用自有闲置资金投资理财产品

• 为提升资金使用效率，公司及其合并报表范围内子公司获准在不影响正常经营及研发、生产、建设资金需求的前提下，投资不超过人民币20亿元的理财产品（包括但不限于银行、信托、证券公司等发行），额度可滚动使用，使用期限不超过12个月。
• 此举有望提升资金收益，但需注意理财产品的流动性及潜在风险，或对公司财务状况产生正面影响。
• 董事会授权经营管理层具体实施，授权期限为一年。

二、使用部分闲置募集资金进行现金管理

• 公司通过议案，同意使用不超过人民币7.6亿元的闲置募集资金进行现金管理（可循环滚动使用），期限不超过12个月。
• 该资金安排不会影响募投项目及公司正常运营，有望增加公司资金收益。
• 国联民生证券承销保荐有限公司已发表核查意见，确保合规性。

三、开展套期保值型金融衍生品交易业务

• 公司及子公司获准在不影响正常经营的情况下，使用自有资金适度开展总额不超过4000万美元（或等值其他币种）的套期保值型金融衍生品交易业务，额度可滚动使用，期限不超过12个月。
• 该举措旨在规避和防范汇率、利率波动风险，合理控制汇兑损益风险，有助于稳定公司利润。
• 相关议案已通过董事会审计委员会审议。

四、向银行申请综合授信额度

• 公司及其子公司拟向银行申请总额度不超过人民币26亿元、期限不超过三年的综合授信（涵盖流动资金贷款、固定资产贷款、银行承兑汇票、保函、信用证、贸易融资、票据贴现等）。
• 最终融资金额将视公司经营需求及各家银行审批为准，授信额度可循环使用。此举有利于增强公司资金灵活性，支持业务扩展。
• 董事长或其授权人士获得办理相关手续的授权。

五、为控股子公司提供担保

• 公司将为控股子公司SALUBRIS BIOTHERAPEUTICS, INC.（信立泰生物技术有限公司）向工行深圳喜年支行申请不超过3.5亿元融资授信，提供连带责任保证担保，期限三年。
• 此担保有助于子公司融资及业务发展，但增加公司整体担保风险。
• 相关议案已通过董事会审计委员会审议。

六、与诺和晟泰签署协议，获得STC007独家许可权益

• 公司与成都诺和晟泰生物科技有限公司签署协议，获得STC007（瘙痒适应症）在中国市场（含大陆、港澳台）原料药及制剂相关知识产权、许可技术的独家权益，涵盖研发、注册、生产和商业化。
• 公司将根据交易及研发进展，以自筹资金支付首付款及研发里程碑款合计不超1.25亿元。如产品获批上市、销售额达约定标准，将支付销售里程碑款累计最高不超7.25亿元，此外还需按协议比例支付销售提成。
• 此次交易有望丰富公司慢病创新产品管线，对公司未来成长空间及市场竞争力提升具有重大意义，若研发及上市进展顺利，或对公司业绩及股价产生积极影响。
• 董事会已授权管理层具体签署及履行相关协议。

投资者关注要点

• 本次董事会决议涉及大额资金运作、金融衍生品、银行授信、子公司担保及重磅创新药品独家权益引进，均为潜在股价敏感事项。
• 尤其是STC007独家权益的获得，若未来产品上市和销售快速增长，有望显著提升公司业绩和市值。
• 需关注理财、衍生品、担保等业务可能带来的风险及合规执行情况。

免责声明： 本文信息基于公司公告，不构成任何投资建议。投资者应对相关事项保持关注，理性决策并自行承担投资风险。

Salubris: Detailed Board Resolutions—Key Points for Investors

1. Utilization of Idle Own Funds for Wealth Management Products

• To enhance capital utilization efficiency, Salubris and its consolidated subsidiaries are authorized to invest up to RMB 2 billion of idle funds in wealth management products (from banks, trusts, securities companies, etc.) for up to 12 months, with a rolling use of quota.
• This measure may improve financial returns but also carries liquidity and investment risks, potentially impacting the company’s financial performance positively.
• The management is authorized to execute these investments for one year.

2. Cash Management of Idle Raised Funds

• The company is allowed to use up to RMB 760 million of idle raised funds for cash management within 12 months, with funds recyclable within the quota.
• This is expected to increase capital returns without affecting the use of raised funds for intended projects or daily operations.
• Guolian Minsheng Securities has issued a compliance review opinion.

3. Hedging Financial Derivatives Transactions

• Salubris and its subsidiaries are authorized to use own funds to conduct hedging transactions in financial derivatives up to USD 40 million (or equivalent in other currencies) within 12 months.
• This aims to manage exchange and interest rate risks, potentially stabilizing profits, but also introduces derivative trading risks.
• Reviewed and approved by the board’s audit committee.

4. Application for Bank Comprehensive Credit Line

• The company and its subsidiaries will apply for a total comprehensive credit line of up to RMB 2.6 billion from banks for up to three years (including loans, bills, guarantees, L/Cs, trade finance, etc.).
• Final financing depends on approval and actual demand, with the quota being reusable. This move enhances financial flexibility and supports business growth.
• Board chairman or authorized persons are empowered to handle related procedures.

5. Guarantee for Subsidiary Financing

• The company will provide a joint and several liability guarantee for its subsidiary SALUBRIS BIOTHERAPEUTICS, INC. for up to RMB 350 million in financing from ICBC Shenzhen Xinian Branch, for three years.
• This will help the subsidiary’s financing and development but will increase the parent company’s guarantee risk.
• Reviewed by the audit committee.

6. Exclusive License Rights of STC007 from Nuoheshengtai

• Salubris signed an agreement with Chengdu Nuoheshengtai Biotech to obtain exclusive rights in China (mainland, Hong Kong, Macau, Taiwan) for STC007 (for pruritus indications), including R&D, registration, manufacturing, and commercialization.
• Payment includes an upfront and milestone payments up to RMB 125 million, and sales milestones up to RMB 725 million if the product is approved and sales reach the contract target, plus sales royalties.
• This move enriches Salubris’s chronic disease innovative pipeline and, if successful, could substantially boost the company’s growth prospects and market value.
• Management is authorized to sign and implement relevant agreements.

Key Investor Takeaways

• The board resolutions involve significant capital operations, derivatives, credit lines, guarantees, and a major innovative drug license—all potentially price-sensitive events.
• The exclusive STC007 license, in particular, could drive future revenue and valuation if the product launches successfully.
• Investors should also monitor execution risks and compliance in wealth management, derivatives, and guarantee operations.

Disclaimer: The content above is based on company disclosures and does not constitute investment advice. Investors should make decisions prudently and assume relevant risks.

View 信立泰 Historical chart here